Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma

다국어 초록 (Multilingual Abstract)

Background: Mechanism and predictive biomarkers for tyrosine kinase inhibitor (TKI) resistance of advanced clear cell renal cell carcinoma (ccRCC) have not been fully evaluated.
Methods: We performed gene expression profiling on samples from an acquired TKI resistance cohort that consisted of 10 cases of TKI-treated ccRCC patients with matched tumor tissues harvested at pre-treatment and TKI-resistant post-treatment periods. In addition, a public microarray dataset from patient-derived xenograft model for TKI-treated ccRCC (GSE76068) was retrieved. Commonly altered pathways between the datasets were investigated by Ingenuity Pathway Analysis using commonly regulated differently expressed genes (DEGs). The significance of candidate DEG on intrinsic TKI resistance was assessed through immunohistochemistry in a separate cohort of 101 TKI-treated ccRCC cases.
Results: TNFRSF1A gene expression and tumor necrosis factor (TNF)-α pathway were upregulated in ccRCCs with acquired TKI resistance in both microarray datasets. Also, high expression (> 10% of labeled tumor cells) of TNF receptor 1 (TNFR1), the protein product of TNFRSF1A gene, was correlated with sarcomatoid dedifferentiation and was an independent predictive factor of clinically unfavorable response and shorter survivals in separated TKI- treated ccRCC cohort.
Conclusion: TNF-α signaling may play a role in TKI resistance, and TNFR1 expression may serve as a predictive biomarker for clinically unfavorable TKI responses in ccRCC.

참고문헌 (Reference)

1 Robin X, "pROC : an open-source package for R and S+ to analyze and compare ROC curves" 12 (12): 77-, 2011

2 Moch H, "WHO Classification of Tumours of the Urinary System and Male Genital Organs" IARC 18-21, 2015

3 Balkwill F, "Tumour necrosis factor and cancer" 9 (9): 361-371, 2009

4 Chuang MJ, "Tumor-derived tumor necrosis factoralpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells" 99 (99): 905-913, 2008

5 Al-Lamki RS, "Tumor necrosis factor receptor expression and signaling in renal cell carcinoma" 177 (177): 943-954, 2010

6 Wang LC, "Tumor necrosis factor alpha-dependent drug resistance to purine and pyrimidine analogues in human colon tumor cells mediated through IKK" 280 (280): 7634-7644, 2005

7 Harrison ML, "Tumor necrosis factor alpha as a new target for renal cell carcinoma : two sequential phase II trials of infliximab at standard and high dose" 25 (25): 4542-4549, 2007

8 Zhang Z, "Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells" 37 (37): 3456-3470, 2018

9 Godwin P, "Targeting nuclear factor-kappa B to overcome resistance to chemotherapy" 3 : 120-, 2013

10 Wajant H, "TNFR1 and TNFR2 in the control of the life and death balance of macrophages" 7 : 91-, 2019

11 Ho MY, "TNF-α induces epithelial-mesenchymal transition of renal cell carcinoma cells via a GSK3β-dependent mechanism" 10 (10): 1109-1119, 2012

12 Gong K, "TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer" 128 (128): 2500-2518, 2018

13 Wu Y, "TNF-alpha/NF-kappaB/snail pathway in cancer cell migration and invasion" 102 (102): 639-644, 2010

14 Rao A, "Survival outcomes for advanced kidney cancer patients in the era of targeted therapies" 6 (6): 165-, 2018

15 Aggarwal BB, "Signalling pathways of the TNF superfamily : a double-edged sword" 3 (3): 745-756, 2003

16 Manley BJ, "Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components" 5 (5): S160-S165, 2016

17 Conant JL, "Sarcomatoid renal cell carcinoma is an example of epithelial--mesenchymal transition" 64 (64): 1088-1092, 2011

18 Park JY, "Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factortargeted therapy" 45 (45): 1437-1444, 2014

19 Rini BI, "Resistance to targeted therapy in renal-cell carcinoma" 10 (10): 992-1000, 2009

20 Makhov P, "Resistance to systemic therapies in clear cell renal cell carcinoma : mechanisms and management strategies" 17 (17): 1355-1364, 2018

21 Hayden MS, "Regulation of NF-κB by TNF family cytokines" 26 (26): 253-266, 2014

22 Okada A, "Recent advances in pathophysiology and surgical treatment of congenital dilatation of the bile duct" 9 (9): 342-351, 2002

23 Motzer RJ, "Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma" 113 (113): 1552-1558, 2008

24 Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)" 45 (45): 228-247, 2009

25 Chen F, "New insights into the role of nuclear factor-kappaB in cell growth regulation" 159 (159): 387-397, 2001

26 Ting AT, "More to life than NF-κB in TNFR1 signaling" 37 (37): 535-545, 2016

27 Lovly CM, "Molecular pathways : resistance to kinase inhibitors and implications for therapeutic strategies" 20 (20): 2249-2256, 2014

28 Lamouille S, "Molecular mechanisms of epithelial-mesenchymal transition" 15 (15): 178-196, 2014

29 Bielecka ZF, "Mechanisms of acquired resistance to tyrosine kinase inhibitors in clear-cell renal cell carcinoma(ccRCC)" 8 (8): 218-228, 2014

30 Diaz-Montero CM, "MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model" 115 (115): 920-928, 2016

31 Ali A, "Investigating various thresholds as immunohistochemistry cutoffs for observer agreement" 25 (25): 599-608, 2017

32 Wang J, "Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced nonsmall-cell lung cancer with activating EGFR mutations" 9 : 3711-3726, 2016

33 Perez-Gracia JL, "Identification of TNFalpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array" 101 (101): 1876-1883, 2009

34 Bi M, "Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma" 113 (113): 2170-2175, 2016

35 Malouf GG, "Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations" 70 (70): 348-357, 2016

36 Subramanian A, "Gene set enrichment analysis : a knowledge-based approach for interpreting genome-wide expression profiles" 102 (102): 15545-15550, 2005

37 Mikami S, "Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas" 136 (136): 1504-1514, 2015

38 Hwang HS, "Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma" 99 (99): 659-670, 2019

39 Go H, "Development of response classifier for vascular endothelial growth factor receptor(VEGFR)-tyrosine kinase inhibitor(TKI)in metastatic renal cell carcinoma" 25 (25): 51-58, 2019

40 Budczies J, "Cutoff Finder : a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization" 7 (7): e51862-, 2012

41 Siegel RL, "Cancer statistics, 2019" 69 (69): 7-34, 2019

42 Smyth GK, "Bioinformatics and Computational Biology Solutions Using R and Bioconductor" Springer 397-420, 2005